0

GlycoMimetics (GLYC) Surges 100% On Breakthrough Therapy Designation

On Thursday, GlycoMimetics (NASDAQ:GLYC) surged as high 100% after the company announced that it had received FDA breakthrough therapy designation. The drug that got the designation is the one that is known as GMI-1271. This drug was developed to treat… Continue Reading

0

Merck Receives FDA Approval For Keytruda Treating Lung Cancer

This past week Merck (NYSE:MRK) received FDA approval for its drug Keytruda in treating patients with advanced lung cancer. Although, the drug was approved in the condition on that it be combined with chemotherapy. This is good news, because the… Continue Reading

0

Conatus Pharmaceuticals (CNAT) Launches Small Offering For Pipeline Expansion

On Thursday, Conatus Pharmaceuticals (NASDAQ:CNAT) announced an offering to sell 5.2 million shares of common stock priced at $5.50 per share.  The amount that the company will obtain will be before underwriter discounts, commissions, and offering costs. The expected gross… Continue Reading

0

Ardelyx Shares Plummet 37% Despite Passing Primary Endpoint Of Phase 3

On Friday, Ardelyx (NASDAQ:ARDX) shares plummeted 37% despite passing the primary endpoint of a phase 3 study. The company tested its drug Tenapanor in a phase 3 clinical trial known as T3MPO-1. The trial recruited patients with a disease known… Continue Reading

0

Seattle Genetics Eliminates $2 Billion Deal With Immunomedics

On Friday,  it was announced that Seattle Genetics (NASDAQ:SGEN) had ended a potential $2 billion deal with Immunomedics (NASDAQ:IMMU). The initial deal was proposed back in February of this year. The deal was created for a licensing deal relating to… Continue Reading

0

Aduro Biotech (ADRO) Closes Down Trial On Safety Issue For Main Drug

On Monday, Aduro Biotech (NASDAQ:ADRO) fell as much as 22% after the company announced that a patient tested positive for listeria. Due to this development the FDA had to place the clinical trials on a partial hold. The clinical trials… Continue Reading

0

Array Biopharma (ARRY) Announces Successful Phase 3 Results In Patients With Melanoma

On Monday, Array Biopharma (NASDAQ:ARRY) shares gained 80% after the company announced positive results in its phase 3 clinical trial treating patients with metastatic melanoma. More specifically the clinical trial met on the primary endpoint of the phase 3 study.… Continue Reading